Genmab Submits Application in Japan for Multiple Myeloma Combo

• Supplemental new drug application (sNDA) submitted in Japan for daratumumab in combination with lenalidomide and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem cell transplant
• Submission based on data from Phase III MAIA study

https://www.marketscreener.com/GENMAB-1412914/news/Genmab-Announces-Submission-of-Supplemental-New-Drug-Application-in-Japan-for-Daratumumab-in-Combi-28357151/